Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
SURMOUNT-1 Tirzepatide The pivotal tirzepatide trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks
Tirzepatide produced a mean weight reduction of 20.2% compared to 13.7% with semaglutide a statistically significant 6.5 percentage point difference
Chronic alcohol use increases oxidative stress, further elevating homocysteine levels
All materials are intended strictly for laboratory research, analytical testing, and scientific investigation
US$ 26.64
US$ 29.73
US$ 25.17
US$ 28.84
